Evidence map›Paper›PMID 36590587›Full record

ArticleFrontiers in cellular and infection microbiology2022

Performance of D-dimer to lymphocyte ratio in predicting the mortality of COVID-19 patients.

Fei Peng, Qiong Yi, Quan Zhang, Jiayi Deng, Cheng Li, Min Xu, Chenfang Wu, Yanjun Zhong, Shangjie Wu

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fei PengDepartment of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Qiong YiDepartment of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Quan ZhangDepartment of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Jiayi DengCritical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Cheng LiDepartment of respiratory medicine, Hunan Provincial People's Hospital, Changsha, China.
Min XuCritical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Chenfang WuCritical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Yanjun ZhongCritical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Shangjie WuDepartment of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nowadays, there is still no effective treatment developed for COVID-19, and early identification and supportive therapies are essential in reducing the morbidity and mortality of COVID-19. This is the first study to evaluate D-dimer to lymphocyte ratio (DLR) as a prognostic utility in patients with COVID-19. Methods: We retrospectively analyzed 611 patients and separated them into groups of survivors and non-survivors. The area under the curve (AUC) of various predictors integrated into the prognosis of COVID-19 was compared using the receiver operating characteristic (ROC) curve. In order to ascertain the interaction between DLR and survival in COVID-19 patients, the Kaplan-Meier (KM) curve was chosen. Results: Age ( Conclusion: DLR might indicate a risk factor in the mortality of patients with COVID-19.

Indexed as

COVID-19Fibrin Fibrinogen Degradation ProductsHumansLymphocytesNeutrophilsRetrospective StudiesFibrin Fibrinogen Degradation Productsfibrin fragment DCOVID-19D-dimerD-dimer to lymphocyte ratioimmunothrombosislymphocytemortality

Identifiers

PMID36590587
PMCPMC9797859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.